Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 32.91
SGMO's Cash-to-Debt is ranked lower than
51% of the 983 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. SGMO: 32.91 )
Ranked among companies with meaningful Cash-to-Debt only.
SGMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.71  Med: No Debt Max: No Debt
Current: 32.91
Equity-to-Asset 0.86
SGMO's Equity-to-Asset is ranked higher than
78% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SGMO: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
SGMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.88 Max: 0.99
Current: 0.86
0.39
0.99
Interest Coverage N/A
SGMO's Interest Coverage is ranked lower than
55% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGMO: N/A )
Ranked among companies with meaningful Interest Coverage only.
SGMO' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 1
Altman Z-Score: 11.79
Beneish M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -385.07
SGMO's Operating Margin % is ranked lower than
65% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. SGMO: -385.07 )
Ranked among companies with meaningful Operating Margin % only.
SGMO' s Operating Margin % Range Over the Past 10 Years
Min: -385.07  Med: -119.18 Max: -58.38
Current: -385.07
-385.07
-58.38
Net Margin % -380.44
SGMO's Net Margin % is ranked lower than
66% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. SGMO: -380.44 )
Ranked among companies with meaningful Net Margin % only.
SGMO' s Net Margin % Range Over the Past 10 Years
Min: -380.44  Med: -114.89 Max: -57.59
Current: -380.44
-380.44
-57.59
ROE % -48.18
SGMO's ROE % is ranked lower than
57% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. SGMO: -48.18 )
Ranked among companies with meaningful ROE % only.
SGMO' s ROE % Range Over the Past 10 Years
Min: -52.56  Med: -33.13 Max: -16.09
Current: -48.18
-52.56
-16.09
ROA % -42.35
SGMO's ROA % is ranked lower than
60% of the 992 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. SGMO: -42.35 )
Ranked among companies with meaningful ROA % only.
SGMO' s ROA % Range Over the Past 10 Years
Min: -47.56  Med: -28.49 Max: -13.76
Current: -42.35
-47.56
-13.76
ROC (Joel Greenblatt) % -1458.83
SGMO's ROC (Joel Greenblatt) % is ranked lower than
66% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: -369.38 vs. SGMO: -1458.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SGMO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2186.87  Med: -1671.55 Max: -1066.04
Current: -1458.83
-2186.87
-1066.04
3-Year Revenue Growth Rate -13.90
SGMO's 3-Year Revenue Growth Rate is ranked lower than
70% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SGMO: -13.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SGMO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.3  Med: -2.15 Max: 67.4
Current: -13.9
-37.3
67.4
3-Year EBITDA Growth Rate 29.50
SGMO's 3-Year EBITDA Growth Rate is ranked higher than
81% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. SGMO: 29.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SGMO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -23.7  Med: 5.25 Max: 104.7
Current: 29.5
-23.7
104.7
3-Year EPS without NRI Growth Rate 28.60
SGMO's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 553 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. SGMO: 28.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SGMO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -25.2  Med: 0.15 Max: 184.4
Current: 28.6
-25.2
184.4
GuruFocus has detected 5 Warning Signs with Sangamo Therapeutics Inc $SGMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGMO's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:NK, NAS:ANIP, NAS:AKBA, NAS:SPPI, OTCPK:SNBIF, NAS:RXDX, NAS:CARA, NAS:CALA, NAS:RGNX, OTCPK:SXMDF, NAS:CTMX, NAS:JNCE, NAS:AMAG, NAS:AUPH, NAS:VSAR, NAS:ACHN, NAS:WVE, NAS:INO, NAS:ACIU, NAS:LJPC » details
Traded in other countries:GBY.Germany, SGMO.Switzerland, 0R1D.UK,
Headquarter Location:USA
Sangamo Therapeutics Inc is a clinical stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Sangamo Therapeutics Inc was incorporated in the State of Delaware on June 22, 1995. The Company is engaged in translating ground-breaking science into genomic therapies that transform patients' lives using the company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Its proprietary zinc finger DNA-binding proteins (ZFP) technology enables efficient and highly specific genome editing and gene regulation, and are developing genome editing and gene therapies for the treatment of genetically tractable diseases.

Ratios

vs
industry
vs
history
PB Ratio 5.25
SGMO's PB Ratio is ranked lower than
54% of the 888 Companies
in the Global Biotechnology industry.

( Industry Median: 3.78 vs. SGMO: 5.25 )
Ranked among companies with meaningful PB Ratio only.
SGMO' s PB Ratio Range Over the Past 10 Years
Min: 1.47  Med: 4.02 Max: 11.13
Current: 5.25
1.47
11.13
PS Ratio 34.46
SGMO's PS Ratio is ranked lower than
70% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.91 vs. SGMO: 34.46 )
Ranked among companies with meaningful PS Ratio only.
SGMO' s PS Ratio Range Over the Past 10 Years
Min: 4.84  Med: 19.27 Max: 78.78
Current: 34.46
4.84
78.78
EV-to-EBIT -7.38
SGMO's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 22.66 vs. SGMO: -7.38 )
Ranked among companies with meaningful EV-to-EBIT only.
SGMO' s EV-to-EBIT Range Over the Past 10 Years
Min: -45.3  Med: -9.1 Max: -0.9
Current: -7.38
-45.3
-0.9
EV-to-EBITDA -7.49
SGMO's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.28 vs. SGMO: -7.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.3  Med: -9.4 Max: -0.9
Current: -7.49
-46.3
-0.9
Current Ratio 10.24
SGMO's Current Ratio is ranked higher than
80% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. SGMO: 10.24 )
Ranked among companies with meaningful Current Ratio only.
SGMO' s Current Ratio Range Over the Past 10 Years
Min: 5.06  Med: 11.9 Max: 55.31
Current: 10.24
5.06
55.31
Quick Ratio 10.24
SGMO's Quick Ratio is ranked higher than
80% of the 976 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SGMO: 10.24 )
Ranked among companies with meaningful Quick Ratio only.
SGMO' s Quick Ratio Range Over the Past 10 Years
Min: 5.06  Med: 11.9 Max: 55.31
Current: 10.24
5.06
55.31
Days Sales Outstanding 46.44
SGMO's Days Sales Outstanding is ranked higher than
66% of the 627 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. SGMO: 46.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.14  Med: 27.89 Max: 93.6
Current: 46.44
1.14
93.6

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
SGMO's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. SGMO: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.2  Med: -9.1 Max: -1.1
Current: -4.4
-61.2
-1.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.09
SGMO's Price-to-Net-Cash is ranked higher than
63% of the 532 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. SGMO: 6.09 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGMO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.96  Med: 4 Max: 17.78
Current: 6.09
0.96
17.78
Price-to-Net-Current-Asset-Value 5.86
SGMO's Price-to-Net-Current-Asset-Value is ranked higher than
64% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. SGMO: 5.86 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGMO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.93  Med: 3.9 Max: 17.45
Current: 5.86
0.93
17.45
Price-to-Tangible-Book 5.32
SGMO's Price-to-Tangible-Book is ranked higher than
54% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. SGMO: 5.32 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGMO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.89  Med: 3.73 Max: 12.57
Current: 5.32
0.89
12.57
Price-to-Median-PS-Value 1.79
SGMO's Price-to-Median-PS-Value is ranked lower than
75% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. SGMO: 1.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SGMO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.22 Max: 9.57
Current: 1.79
0.3
9.57
Earnings Yield (Greenblatt) % -13.55
SGMO's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.87 vs. SGMO: -13.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGMO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -110.2  Med: -11 Max: -2.2
Current: -13.55
-110.2
-2.2

More Statistics

Revenue (TTM) (Mil) $18.87
EPS (TTM) $ -1.02
Beta4.08
Short Percentage of Float14.68%
52-Week Range $2.65 - 9.35
Shares Outstanding (Mil)69.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 21 16 12
EPS ($) -1.00 -1.26 -1.37
EPS without NRI ($) -1.00 -1.26 -1.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SGMO

Headlines

Articles On GuruFocus.com
180LA Wins Gold and Bronze Cannes Lions for Expedia and VisitBritain's "Visit Britain" Interactive F Jun 23 2017 
Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in A Jun 23 2017 
Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis a Jun 23 2017 
TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland Jun 23 2017 
Applied Ventures Ramps Investment in Korea with New Innovation Fund Jun 22 2017 
Evolent Health, Inc. Announces Pricing of Secondary Public Offering of Class A Common Stock Jun 22 2017 
SEACOR Marine Announces “Stalking Horse” Bid to Form Joint Venture With Montco Offshore, I Jun 22 2017 
Greenbrier announces webcast and conference call of quarterly financial results Jun 22 2017 
NXT Energy Solutions Announces Results of Annual General Meeting Jun 22 2017 
Motif Bio Announces Result of General Meeting and Total Voting Rights Jun 22 2017 

More From Other Websites
Here's Why Sangamo Therapeutics Rose as Much as 11.7% Today Jun 22 2017
3 Stocks to Watch on Wednesday: Carmax, Inc (KMX), Adobe Systems Incorporated (ADBE) and Sangamo... Jun 21 2017
Sangamo Therapeutics Announces Pricing Of $72.5 Million Public Offering Of Common Stock Jun 21 2017
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock Jun 20 2017
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy... Jun 07 2017
ETFs with exposure to Sangamo Therapeutics, Inc. : June 5, 2017 Jun 05 2017
Sangamo Therapeutics Announces Presentation At The Jefferies 2017 Global Healthcare Conference Jun 02 2017
Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma... Jun 02 2017
ETFs with exposure to Sangamo Therapeutics, Inc. : May 25, 2017 May 25 2017
Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 May 24 2017
Will Sangamo Therapeutics (SGMO) Continue to Surge Higher? May 18 2017
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status May 17 2017
Edited Transcript of SGMO earnings conference call or presentation 10-May-17 9:00pm GMT May 17 2017
Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene... May 16 2017
Sangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II... May 15 2017
Is the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock? May 15 2017
Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual... May 15 2017
Why Sangamo Therapeutics Inc. Jumped Higher Today May 12 2017
Today's Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Sangamo Therapeutics May 12 2017
Sangamo Therapeutics, Inc. – Value Analysis (NASDAQ:SGMO) : May 11, 2017 May 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}